



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/421374/2018

## European Medicines Agency decision

P/0198/2018

of 19 July 2018

on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMA-001310-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0198/2018

of 19 July 2018

on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMA-001310-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the European Medicines Agency's decision P/0073/2013 issued on 26 March 2013, the decision P/0147/2015 issued on 10 July 2015 and the decision P/0250/2015 issued on 30 October 2015,

Having regard to the application submitted by PHARM Srl on 12 March 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 June 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for gabapentin, oral solution, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to PHARM Srl, via Eistein, Localita' Cascina Codazza, 26900 – Lodi, Italy.

EMA/PDCO/169468/2018

London, 1 June 2018

## Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001310-PIP01-12-M03

### Scope of the application

**Active substance(s):**

Gabapentin

**Condition(s):**

Treatment of chronic pain

**Pharmaceutical form(s):**

Oral solution

**Route(s) of administration:**

Oral use

**Name / corporate name of the PIP applicant:**

PHARM Srl

### Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, PHARM Srl submitted to the European Medicines Agency on 12 March 2018 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0073/2013 issued on 26 March 2013, the decision P/0147/2015 issued on 10 July 2015 and the decision P/0250/2015 issued on 30 October 2015.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 April 2018.

## Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Condition:

Treatment of chronic pain

The waiver applies to:

- the paediatric population from birth to less than 3 months of age;
- oral solution, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

# 2. Paediatric Investigation Plan

## 2.1. Condition:

Treatment of chronic pain

### 2.1.1. Indication(s) targeted by the PIP

Treatment of chronic pain of neuropathic origin

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 months to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Oral solution

### 2.1.4. Measures

| Area         | Number of measures | Description                                                                                                                                                                                                                                                                                             |
|--------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quality      | 1                  | <b>Measure 1</b><br>Development of an age-appropriate 75 mg /ml oral solution.                                                                                                                                                                                                                          |
| Non-clinical | 1                  | <b>Measure 2</b><br>Juvenile repeated rat toxicity study.                                                                                                                                                                                                                                               |
| Clinical     | 3                  | <b>Measure 3</b><br>Randomised, double-blind, double-dummy, active-controlled, multi-centre trial to evaluate the pharmacokinetic, efficacy and safety of gabapentin liquid formulation in children from 3 months to less than 18 years of age experiencing moderate chronic neuropathic or mixed pain. |

|  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  |  | <p><b>Measure 4</b></p> <p>A randomised, double blind, placebo controlled multi-centre trial to evaluate the safety, pharmacokinetic and efficacy of gabapentin as add-on to morphine in children from 3 months to less than 18 years of age suffering from severe chronic neuropathic or mixed pain.</p> <p><b>Measure 5</b></p> <p>Model-based bridging of clinical data for children from 3 months to less than 3 years.</p> |
|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### 3. Follow-up, completion and deferral of PIP

|                                                                                       |              |
|---------------------------------------------------------------------------------------|--------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes          |
| Date of completion of the paediatric investigation plan:                              | By June 2020 |
| Deferral for one or more measures contained in the paediatric investigation plan:     | No           |